Trans-resveratrol extract from Polygonum Cuspidatum 1g three times a day for 2 weeks

Obesity

Diabetes

Resveratrol

Placebo

Khoo Teck Puat Hospital

Effects of High-Dose Resveratrol in Non-Diabetic Obese Males

Effects of High-Dose Resveratrol on Resting Energy Expenditure and HOMA in Non-Diabetic Obese Males

Measured in Kcal/day using a metabolic cart

Beta cell function, B (%),Insulin sensitivity, S (%), Insulin resistance, IR

Systolic and diastolic blood pressure in mmHg

Goh Kian Peng

National Medical Research Council (NMRC), Singapore

Subjects in the group "resveratrol first" will be submitted to: 30 days of treatment with Transmax (resveratrol, 500 mg, Biotivia Bioceuticals LLC), one tablet/day in the morning at fasting; then to 30 days of wash-out (no supplementation), and then to 30 days of treatment with placebo (one tablet/day in the morning at fasting).

Subjects in the group "Placebo first" will be submitted to: 30 days of treatment with placebo, one tablet/day in the morning at fasting; than to 30 days of wash-out (no supplementation), and then to 30 days of treatment with Transmax (resveratrol, 500 mg) (one tablet/day in the morning at fasting).

Chronic Subclinic Inflammation

Redox Status

Subjects in the group "resvetarol first" will be submitted to: 30 days of treatment with Transmax (resveratrol, 500 mg, Biotivia Bioceuticals LLC), one tablet/day in the morning at fasting; then to 30 days of wash-out (no supplementation), and then to 30 days of treatment with placebo (one tablet/day in the morning at fasting).

resveratrol

Simona Bo

Anti-inflammatory and Antioxidant Effects of Resveratrol on Healthy Adults.

Double-blind Cross-over Randomised Controlled Trial on the Anti-inflammatory and Antioxidant Effects of Resveratrol on Healthy Adults.

To evaluate before-after changes in circulating concentrations of C-reactive protein (CRP), an inflammation marker, in smokers submitted to resveratrol supplementation when compared to smokers treated with placebo

To evaluate before-after changes in circulating fasting concentrations of the following parameters:
-markers of oxidative stress: TAS (total antioxidant status.

To evaluate before-after changes in circulating fasting concentrations of the following parameters:
-markers of oxidative stress: 4-hydroxynonenal

To evaluate before-after changes in circulating fasting concentrations of the following parameters:
-markers of oxidative stress: nitrotyrosine.

To evaluate before-after changes in circulating fasting concentrations of the following parameters:
-markers of oxidative stress: endothelial nitric oxide synthase (eNOS)-polymorphism

To evaluate before-after changes in circulating fasting concentrations of the following parameters:
-markers of oxidative stress: superoxide dismutase (SOD2)-polymorphism.

To evaluate before-after changes in circulating fasting concentrations of the following parameters:
-markers of oxidative stress: catalase-polymorphism

To evaluate before-after changes in circulating fasting concentrations of the following parameters:
-other markers of inflammation: interleukin-6.

To evaluate before-after changes in circulating fasting concentrations of the following parameters:
-other markers of inflammation: pentraxin 3.

To evaluate before-after changes in circulating fasting concentrations of the following parameters:
-other markers of inflammation: tumor necrosis factor-α.

MD, Department of Internal Medicine

University of Turin, Italy

10 normal weight women with PCOS who have normal abdominal adiposity established by DEXA

10 normal weight women with PCOS who have increased abdominal adiposity established by DEXA

10 normal weight ovulatory women serving as controls who have normal abdominal adiposity established by DEXA

10 normal weight ovulatory women serving as controls who have increased abdominal adiposity established by DEXA

10 obese ovulatory women serving as controls

Polycystic Ovary Syndrome

4 out of 10 subjects will receive salsalate 2.0 gm twice a day for 12 weeks; 4 out of 10 subjects will receive PCE 200 mg containing 20% resveratrol twice a day for 12 weeks.

Salsalate

4 out of the 10 subjects will receive salsalate 2.0 gm twice a day for 12 weeks; 4 out of 10 subjects will receive PCE 200 mg containing 20% resveratrol twice a day for 12 weeks.

Indiana University Reproductive Endocrine and Inflammation Research Program

Indiana University Hospital

Evaluation of Oral Lipid Ingestion in Relation to Ovarian Androgen Secretion in Polycystic Ovary Syndrome (PCOS)

Evaluation of the Ovarian Dynamic Response and the Inflammatory Response to Oral Lipid Challenge in Relation to Body Composition in Polycystic Ovary Syndrome

This outcome along with insulin sensitivity derived from an oral glucose tolerance test (OGTT) and body composition measured by dual energy absorptiometry (DEXA) will be assessed in all study subjects (PCOS and controls).

This outcome will be assessed in a subset of normal weight women with PCOS who have either normal (n=4) or increased (n=4) abdominal adiposity.

reynoutria/obesity

Effects of High-Dose Resveratrol in Non-Diabetic Obese Males

Anti-inflammatory and Antioxidant Effects of Resveratrol on Healthy Adults.

Evaluation of Oral Lipid Ingestion in Relation to Ovarian Androgen Secretion in Polycystic Ovary Syndrome (PCOS)

科学支持的最完整的草药数据库